These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19138063)

  • 21. The early estimation of circulating drug metabolites in humans.
    Luffer-Atlas D
    Expert Opin Drug Metab Toxicol; 2012 Aug; 8(8):985-97. PubMed ID: 22681256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meeting the MIST regulations: human metabolism in Phase I using AMS and a tiered bioanalytical approach.
    Lappin G; Seymour M; Gross G; Jørgensen M; Kall M; Kværnø L
    Bioanalysis; 2012 Feb; 4(4):407-16. PubMed ID: 22394141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
    Hosea NA; Collard WT; Cole S; Maurer TS; Fang RX; Jones H; Kakar SM; Nakai Y; Smith BJ; Webster R; Beaumont K
    J Clin Pharmacol; 2009 May; 49(5):513-33. PubMed ID: 19299532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An industry perspective on tiered approach to the investigation of metabolites in drug development.
    Huskey SE; Li W; Mangold JB; Flarakos J
    Bioanalysis; 2014 Mar; 6(5):617-28. PubMed ID: 24620804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and future trends in the application of HPLC-MS to metabolite-identification studies.
    Castro-Perez JM
    Drug Discov Today; 2007 Mar; 12(5-6):249-56. PubMed ID: 17331890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing.
    Espina R; Yu L; Wang J; Tong Z; Vashishtha S; Talaat R; Scatina J; Mutlib A
    Chem Res Toxicol; 2009 Feb; 22(2):299-310. PubMed ID: 18980340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
    Hewitt NJ; de Kanter R; LeCluyse E
    Chem Biol Interact; 2007 May; 168(1):51-65. PubMed ID: 17239835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
    Lappin G; Seymour M
    Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening.
    Tolonen A; Turpeinen M; Pelkonen O
    Drug Discov Today; 2009 Feb; 14(3-4):120-33. PubMed ID: 19059358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A combined approach to drug metabolism and toxicity assessment.
    Ekins S; Andreyev S; Ryabov A; Kirillov E; Rakhmatulin EA; Sorokina S; Bugrim A; Nikolskaya T
    Drug Metab Dispos; 2006 Mar; 34(3):495-503. PubMed ID: 16381662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?
    Obach RS; Nedderman AN; Smith DA
    Xenobiotica; 2012 Jan; 42(1):46-56. PubMed ID: 21992031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retention-time-shift-tolerant background subtraction and noise reduction algorithm (BgS-NoRA) for extraction of drug metabolites in liquid chromatography/mass spectrometry data from biological matrices.
    Zhu P; Ding W; Tong W; Ghosal A; Alton K; Chowdhury S
    Rapid Commun Mass Spectrom; 2009 Jun; 23(11):1563-72. PubMed ID: 19408276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of exposure multiples of human metabolites for MIST assessment in preclinical safety species without using reference standards or radiolabeled compounds.
    Ma S; Li Z; Lee KJ; Chowdhury SK
    Chem Res Toxicol; 2010 Dec; 23(12):1871-3. PubMed ID: 21121646
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances.
    Obach RS
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):81-9. PubMed ID: 19152216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro species comparisons and metabolite identification.
    Dow P
    Curr Protoc Pharmacol; 2006 Oct; Chapter 7():Unit7.10. PubMed ID: 22294177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive tools for the evaluation of microbial effects on drugs during gastrointestinal passage.
    Pieper IA; Bertau M
    Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):747-60. PubMed ID: 20367108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling.
    Gibson CR; Bergman A; Lu P; Kesisoglou F; Denney WS; Mulrooney E
    Xenobiotica; 2009 Sep; 39(9):637-48. PubMed ID: 19480559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
    Prueksaritanont T; Lin JH; Baillie TA
    Toxicol Appl Pharmacol; 2006 Dec; 217(2):143-52. PubMed ID: 17055014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolite quantitation: detector technology and MIST implications.
    Wright P; Miao Z; Shilliday B
    Bioanalysis; 2009 Jul; 1(4):831-45. PubMed ID: 21083141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classification of metabolites with kernel-partial least squares (K-PLS).
    Embrechts MJ; Ekins S
    Drug Metab Dispos; 2007 Mar; 35(3):325-7. PubMed ID: 17142559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.